Dr. Neha Sabnis
About Dr. Neha Sabnis
Dr. Neha Sabnis serves as the Director of Clinical Genomics at PierianDx, where she leads the Customer Success & Validation Services and Customer Support teams. She has a strong academic background in molecular biology and cancer genetics, holding a Ph.D. from Roswell Park Cancer Institute.
Work at PierianDx
Dr. Neha Sabnis has served as the Director of Clinical Genomics at PierianDx since 2019, based in the Pune Area, India. In this role, she has launched and currently leads the Customer Success & Validation Services and Customer Support teams within the India office. Dr. Sabnis also acts as the functional lead for the Customer Support Operations team, which includes bioinformaticians focused on developing customized bioinformatics pipelines for next-generation sequencing (NGS) assays.
Education and Expertise
Dr. Neha Sabnis holds a Doctor of Philosophy (Ph.D.) in Cell/Cellular, Molecular Biology, and Cancer Genetics from the Roswell Park Cancer Institute, where she studied from 2010 to 2016. She also earned a Master of Science (M.Sc.) in Cancer Cell & Molecular Biology from the University of Leicester in 2009, and a Bachelor of Science (B.Sc. Hons) in Biomedical Sciences from the University of Central Lancashire in 2008. Her educational background underpins her expertise in clinical genomics and molecular biology.
Previous Experience at CORE Diagnostics
Before joining PierianDx, Dr. Sabnis worked at CORE Diagnostics in various roles. She served as a Molecular Scientist and Technical Lead for Next Generation Sequencing from 2018 to 2019, where she was a signatory for NGS and RT-PCR based assays. Prior to that, she held the position of Product Manager from 2017 to 2018, where she launched and led the NGS Department, overseeing the validation and commercial launch of NGS-based assays for Lung Cancer, BRCA1/2, and HLA Typing.
Conference Participation
Dr. Neha Sabnis has spoken at several national and international conferences during her tenure at CORE Diagnostics. Her participation in these events highlights her engagement with the scientific community and her commitment to sharing knowledge in the fields of molecular biology and clinical genomics.